Yazar "Eyupoglu, Damla N." için listeleme
-
The Impact of Jak1/Jak2 Inhibitor Ruxolitinib on the Spleen Size and Symptom Burden in Myeloproliferative Diseases
Aktimur, Sude H.; Malkan, Umit Y.; Eyupoglu, Damla N.; Haznedaroglu, Ibrahim C.; Kelkitli, Engin; Atay, Hilmi M.; Turgut, Mehmet (Akad Doktorlar Yayinevi, 2016)Ruxolitinib as a JAK1 and JAK2 inhibitor drug has recently been approved for the treatment of patients with high-or intermediate-risk myelofibrosis with symptomatic splenomegaly. Clinical development of ruxolitinib has ...
